// App-Quantinova.ai

182 : Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission

Researchers

Presenter

  • Iain McInnes

Principal Investigators

  • Josef S Smolen

  • Laure Gossec

  • Vibeke Strand

  • Luminita Pricop

  • Todd Fox

  • Steffen Jugl

  • Corine Gaillez

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Rheumatology, UPMC University Paris 06 and Pitie-Salpétriere Hospital, Paris, FRANCE

  • Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Austria

  • France

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved